Medicine guide
Zenapax
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Daclizumab
- Made by
- Roche Registration Ltd.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Roche Registration Ltd. |
|---|---|
| Active substance | Daclizumab |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L04AA08 · Cancer treatments and immune-system medicines |
| Authorised on | 1999-02-26 |
| Last updated by the regulator | 2009-02-13 |
| EMA product number | EMEA/H/C/000198 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.